Embecta Corp.
NASDAQ:EMBCDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $345.06M
- Beta
- 0.81
- P/E (TTM)
- 1.6
- EPS (TTM)
- $1.92
- Dividend yield
- 14.79%
Volume 0.72M
Average 1.95M
EMBC Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Embecta Corp.NASDAQ: EMBC
Cost of Revenue · Q2 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q2 FY2026 cost of revenue of $96.6M fell 0.9% year over year, behind the -0.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.
Context
- Cost of revenue amounted to 37.1% of revenue in FY2025, up 2.0 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -0.9% toward the trailing-twelve-month pace of -0.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 400.9M USD
- Year-over-year change
- +1.7%
- 4-year CAGR
- +2.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 400.9M | +1.7% |
| FY2024 | 2024-09-30 | 394.2M | +6.3% |
| FY2023 | 2023-09-30 | 370.9M | +4.6% |
| FY2022 | 2022-09-30 | 354.6M | -2.8% |
| FY2021 | 2021-09-30 | 365M | — |
Cost of Revenue vs competitors
How EMBC compares with its peers on the latest reported figures
- EMBC's LTM Mar 2026 cost of revenue of $390.7M is the 2nd highest of the 11 companies compared; the peer median is $95.21M.
- Its year-over-year change of -0.3% is the 5th highest of 10, against a peer median of -2.6%.
- Cost of revenue amounts to 37.5% of revenue for EMBC, versus a peer median of 60.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.62B | -20.2% | +15.4% | 85.9% | |
| LTM Mar 2026 | $390.7M | -0.3% | +4.2% | 37.5% | |
| LTM Mar 2026 | $376M | -38.7% | -15.3% | 55.6% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Jun 2026 | $136.53M | -10.8% | -3.4% | 65.4% | |
| LTM Jun 2026 | $134.76M | +19.4% | +3.2% | 29.4% | |
| LTM Mar 2026 | $55.67M | -2.6% | +1.4% | 86.3% | |
| LTM Mar 2026 | $47.71M | — | — | 1182.7% | |
| LTM Mar 2026 | $32.49M | +15.1% | +41.7% | 34.6% | |
| LTM Mar 2026 | $18.37M | +7.2% | -4.0% | 36.5% | |
| LTM Mar 2026 | -$114.78M | -122.6% | -73.4% | 175.2% | |
| Peer median (excluding EMBC) | $95.21M | -2.6% | +1.4% | 60.5% | |
Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.13B | 1.12B | 1.12B | 1.08B |
| Cost of Revenue | 365M | 354.6M | 370.9M | 394.2M | 400.9M |
| Gross Profit | 800M | 774.9M | 749.9M | 728.9M | 679.5M |
| Gross Margin | 68.7% | 68.6% | 66.9% | 64.9% | 62.9% |
| Research & Development | 63M | 65M | 85.2M | 78.8M | 21.5M |
| Selling, General & Admin | 240.3M | 294.8M | 341.3M | 365.1M | 331.4M |
| Operating Expenses | 308M | 396.8M | 520.3M | 554.7M | 350.2M |
| Depreciation & Amortization | 38M | 31.7M | 32.7M | 42.5M | 51.1M |
| EBITDA | 533M | 334.5M | 245.4M | 199M | 294.7M |
| EBITDA Margin | 45.8% | 29.6% | 21.9% | 17.7% | 27.3% |
| Operating Income | 492M | 378.1M | 229.6M | 174.2M | 329.3M |
| Operating Margin | 42.2% | 33.5% | 20.5% | 15.5% | 30.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 46.2M | 107M | 112.3M | 107.3M |
| Other Income / Expenses | 3M | (121.5M) | (123.9M) | (130M) | (193M) |
| Income Before Tax | 495M | 256.6M | 105.7M | 44.2M | 136.3M |
| Pre-Tax Margin | 42.5% | 22.7% | 9.4% | 3.9% | 12.6% |
| Income Tax Expense | 80M | 33M | 35.3M | (34.1M) | 40.9M |
| Net Income | 414.8M | 223.6M | 70.4M | 78.3M | 95.4M |
| Net Margin | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% |
| EPS (Basic) | 7.31 | 3.92 | 1.23 | 1.36 | 1.64 |
| EPS (Diluted) | 7.31 | 3.89 | 1.22 | 1.34 | 1.62 |
| Weighted Avg Shares | 56.8M | 57.06M | 57.24M | 58.43M | 58.31M |
| Weighted Avg Shares (Diluted) | 56.8M | 57.06M | 57.76M | 58.33M | 58.92M |
Embecta Corp.
NASDAQ:EMBC
Intrinsic Alpha fair value
Locked
Current Price
$6.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.